Hematology/Oncology

Top Story

Frequently eating organic food may lower cancer risk

October 22, 2018
Meeting NewsPerspective

Chemoradiation should remain standard for HPV-positive oropharyngeal cancer

October 22, 2018
MUNICH — Patients with HPV-positive, low-risk oropharyngeal cancer should undergo chemoradiotherapy instead of cetuximab plus radiotherapy, according to…
Meeting NewsPerspective

First-line pembrolizumab a new standard for recurrent, metastatic head and neck squamous cell carcinoma

October 22, 2018
MUNICH — Pembrolizumab prolonged survival compared with standard first-line systemic therapy for patients with recurrent or metastatic head and neck cancer…
Meeting NewsPerspective

Post-hoc analysis supports pembrolizumab’s benefit in recurrent head, neck squamous cell carcinoma

October 22, 2018
MUNICH — A post-hoc analysis of the randomized phase 3 KEYNOTE-040 trial presented at European Society for Medical Oncology Congress showed a trend toward improved…
Meeting News

SD-101 plus pembrolizumab induces response in recurrent, metastatic head and neck cancer

October 22, 2018
MUNICH — The addition of SD-101 to pembrolizumab induced a promising response rate among patients with recurrent or metastatic head and neck squamous cell…
More Headlines »
CME ABIM MOC

Ace the Case: A 72-Year-Old Man With Fatigue, Weight Loss, and Lymphocytosis

There is no commercial support for this activity.

This educational activity will review the diagnosis and management of a 72-year-old man with complaints of increasing…
More »
Video
Meeting News

Using data to improve quality, develop new relationships

August 15, 2018
More »
Resource Centers
European Society for Medical Oncology Congress

European Society for Medical Oncology Congress

CME CNE CPE

Exploring New Immune Checkpoint Inhibitor Paradigms in Advanced Melanoma

This activity is supported by an educational grant from Bristol-Myers Squibb.

The integration of immune checkpoint inhibitors into treatment algorithms for the management of advanced genitourinary…
More »
Current Issues
View the Current Issue
HemOnc Today